NantHealth & NantOmics to Share Data on Next-Generation Sequencing of Paired DNA & RNA Analysis of Rare Tumors at the America...
June 02 2018 - 4:02PM
Business Wire
Results to be presented during the tumor
biology session at the ASCO 2018 Annual Meeting
NantWorks, LLC today announced that its affiliate companies,
NantHealth, Inc., (NASDAQ: NH), a leading next-generation,
evidence-based, personalized healthcare company and NantOmics, LLC,
the leader in molecular analysis and a member of the NantWorks
ecosystem of companies, will present data on next-generation
sequencing of paired DNA and RNA analysis in patients with rare and
ultra-rare cancers during the tumor biology session at the American
Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event
bringing together 30,000 oncology professionals from June 1-5, 2018
at McCormick Place in Chicago, Illinois. NantWorks will be
exhibiting at booth #7147 during the event.
“New data shows that matched targeted therapy may result in
responses for patients with rare and ultra-rare tumors,” said
Patrick Soon-Shiong, MD, founder of NantWorks. “We look forward to
sharing these results as we continue on our path to building a
future of personalized and improved care.”
Presentation Details
Genomic Landscape of Diverse Rare Tumors: Next-Generation
Sequencing of Paired DNA and RNA analysis, Abstract
#12114WHO: NantHealth, LLC and NantOmics,
LLCWHAT: Tumor Biology SessionWHEN: June 4, 1:15-4:45
PM CSTWHERE: Hall A, McCormick Place
Presentation Summary
The 286 patients involved in this study had been diagnosed with
rare tumor diagnoses. Somatic-specific variants were identified
using paired tumor/normal comprehensive NGS. Analysis was focused
on the 200 most frequently mutated genes in this cohort, and deep
whole transcriptomic sequencing was used to determine expression of
observed somatic variants. The results found that most patients
with rare and ultra-rare cancers had theoretically tractable
alteration, yet not all the DNA alterations were seen in RNA level,
indicating potential silencing at the RNA level.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, is a next-generation, evidence-based, personalized
healthcare company enabling improved patient outcomes and more
effective treatment decisions for critical illnesses. NantHealth's
unique systems-based approach to personalized healthcare applies
novel diagnostics tailored to the specific molecular profiles of
patient tissue and integrates this molecular data in a clinical
setting with large-scale, real-time biometric signal and phenotypic
data to track patient outcomes and deliver precision medicine. For
nearly a decade, NantHealth has developed an adaptive learning
system that integrates our unique molecular profiling solution,
software and hardware. Our system infrastructure collects, indexes,
analyzes and interprets billions of molecular, clinical,
operational and financial data points derived from novel and
traditional sources to continuously improve decision-making and
optimize our clinical pathways and decision algorithms over time.
For more information please visit www.nanthealth.com.
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies,
delivers molecular diagnostic capabilities with the intent of
providing actionable intelligence and molecularly driven decision
support for cancer patients and their providers at the point of
care. NantOmics is the first molecular diagnostics company to
pioneer an integrated approach to unearthing the genomic and
proteomic variances that initiate and drive cancer, by analyzing
both normal and tumor cells from the same patient and following
identified variances through from DNA to RNA to protein to drug.
NantOmics has a highly scalable cloud-based infrastructure capable
of storing and processing thousands of genomes a day, computing
genomic variances in near real-time, and correlating proteomic
pathway analysis with quantitative multi-plexed protein expression
analysis from the same micro-dissected tumor sample used for
genomic analysis. For more information please
visit www.nantomics.com and follow Dr. Soon-Shiong on
Twitter @DrPatSoonShiong.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180602005093/en/
NANTJen Hodsonjhodson@nantworks.comorNANTHenry C.
Jacksoncj@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jun 2024 to Jul 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jul 2023 to Jul 2024